• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
2:40 p.m.Session Objectives and Introduction
 Gail Cassell, Workshop Chair
 Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases
 Eli Lilly and Company
2:45 p.m.Panel Discussion: Proposing Paradigm Shifts
 Gillian Woollett
 Chief Scientist
 Engel & Novitt, LLP
 Frank Gottron
 Specialist in Science and Technology Policy Congressional Research Service
 U.S. Library of Congress
 Thomas Monath
 Partner
 Pandemic and Biodefense Fund
 Kleiner Perkins Caufield & Byers
 Brett Giroir
 Vice Chancellor for Research
 Texas A&M
 Eric Rose
 CEO and Chair, Board of Directors
 Siga Technologies, Inc.
 Bruce Artim
 Director
 Federal Affairs
 Eli Lilly and Company
 Chuck Ludlam
 Former Counsel, Senator Joseph Lieberman
 Former Principal Lobbyist for The Biotechnology Industry Organization
 Phillip Gomez
 Director
 Biodefense and Public Health Practice
 PRTM
3:40 p.m.Discussion with Attendees: What Options Rise to the Top? What Have We Not Considered?
 Gail Cassell, Workshop Chair
 Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases
 Eli Lilly and Company
4:30 p.m.ADJOURN

From: B, Workshop Agenda

Cover of The Public Health Emergency Medical Countermeasures Enterprise
The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary.
Institute of Medicine (US) Forum on Medical and Public Health Preparedness for Catastrophic Events; Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation.
Washington (DC): National Academies Press (US); 2010.
Copyright © 2010, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.